RxDoctor Payments Data

Rosa Huguet, MD

General Practice · Miami, FLNPI 1306824552

Payments from drug & device makers

$14,663in general payments, 2019–2025

Across 234 payments — averaging $62.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$6K
  • AstraZeneca$4K
  • AbbVie$2K
  • Johnson & Johnson$649
  • Phathom Pharmaceuticals, Inc.$496
  • Amarin Pharma, Inc.$333
  • plus $875 from 12 others

What the payments were for

  • Consulting fees$3,00020%
  • Travel & lodging$2,40816%
  • Food & beverage$9,25563%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,663 in reported general payments places this provider in the 95th percentile of 6,901 general practice providers in Florida.

See all general practice providers in Florida

Medicare billing

Part B allowed, 2024
$21,992
Medicare patients
19
Services billed
298

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide19$20,559
FarxigaDapagliflozin Propanediol18$19,469
EliquisApixaban13$14,751
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$10,275
InvokametCanagliflozin/Metformin Hcl11$6,478
Omega-3 Acid Ethyl Esters29$3,871
Cyclosporine12$3,419
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$2,369
Diclofenac Sodium39$1,005
Sodium Polystyrene Sulfonate14$885
Gabapentin79$719
Ciclopirox17$680
Ammonium Lactate28$671
Atorvastatin Calcium124$657
Fluticasone Propionate40$622

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$4,047$29,74434 claims
Lilly USA, LLCMounjaro$238$20,55919 claims
PfizerEliquis$22$14,75113 claims
Johnson & JohnsonInvokamet$649$6,47811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,901 general practice providers in Florida.

Other general practice in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →